Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.47 |
| ▸ | FLT1 | P17948 | 7/20 | 0.47 |
| ▸ | FLT4 | P35916 | 7/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620883 | 1.00 | KDR (0.47) | KDRFLT1FLT4IMPDH2TP53 | |
| SCHEMBL22925774 | 0.88 | TRPV1 (0.48) | KDRFLT1FLT4IMPDH2TRPV1 | |
| SCHEMBL22925921 | 0.86 | VCP (0.46) | KDRFLT1FLT4TP53TRPV1 | |
| SCHEMBL29620940 | 0.86 | VCP (0.46) | KDRFLT1FLT4TP53TRPV1 | |
| SCHEMBL22925908 | 0.82 | GSK3B (0.55) | TP53KDM4EALDH1A1HPGD | |
| SCHEMBL29620989 | 0.82 | GSK3B (0.55) | TP53KDM4EALDH1A1HPGD | |
| SCHEMBL28939252 | 0.80 | KDR (0.42) | KDRFLT1FLT4IMPDH2TP53 | |
| SCHEMBL29620994 | 0.79 | KDR (0.37) | KDRFLT1FLT4TP53TRPV1 | |
| SCHEMBL28733789 | 0.78 | KDR (0.36) | KDRFLT1FLT4IMPDH2TP53 | |
| SCHEMBL22925922 | 0.75 | KDR (0.36) | KDRFLT1FLT4TP53TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | KDR 3951/4885FLT1 2567/4885FLT4 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.